BioSpace News Archive

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370.

In addition to bringing Medicare Advantage to 31 rural counties, the Humana Honor Medicare Advantage plan will be offered statewide, increasing the company’s commitment to veterans

Just in time for Amazon Prime Day, BioLargo, Inc. (OTCQB:BLGO), developer of sustainable life science technologies, today announced that Clyraguard, the personal disinfectant and germicidal spray that safely and easily decontaminates masks and face coverings, is now available at the Clyra Medical Store on Amazon.com.

Surglogs, the first software company to offer a full suite of automated regulatory compliance solutions for healthcare facilities, announced a new partnership with UCHealth, a Colorado nonprofit health care system.

I nitial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors An u pdate from the melanoma & non-melanoma skin cancer patients enrolled into the Phase 1/2 clinical trial of RP1 in combination with Opdivo® (nivolumab) WOBURN, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company deve

EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces unaudited third quarter revenues ending September 30, 2020.

Pediatric Health Care Alliance has completed a merger with New Tampa Pediatrics and Dr. Jaydeep Patel. PHCA has continued plans for expansion in Tampa Bay through new clinical locations and mergers and acquisitions.

IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions such as multiple sclerosis, Crohn’s disease, and rheumatoid arthritis, announced today its acquisition of Precision Healthcare,

Hanger, Inc. (NYSE: HNGR) today announced the promotion and hiring of two senior executives to lead its two business segments, effective Nov. 2, 2020: Regina Weger has been promoted to President, Products & Services; Pete Stoy will join Hanger in the newly formed position of Chief Operating Officer, to lead the Patient Care segment. Vinit Asar, President and Chief Executive Officer (CEO) of Hange

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced the closing of its initial public offering of 6,900,000 shares of its common stock, which includes 900,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional shares, at a public